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Abstract Candida tropicalis is considered the first or the
second non-Candida albicans Candida (NCAC) species
most frequently isolated from candidosis, mainly in patients
admitted in intensive care units (ICUs), especially with
cancer, requiring prolonged catheterization, or receiving
broad-spectrum antibiotics. The proportion of candiduria
and candidemia caused by C. tropicalis varies widely with
geographical area and patient group. Actually, in certain
countries, C. tropicalis is more prevalent, even compared
with C. albicans or other NCAC species. Although
prophylactic treatments with fluconazole cause a decrease
in the frequency of candidosis caused by C. tropicalis, it is
increasingly showing a moderate level of fluconazole
resistance. The propensity of C. tropicalis for dissemination
and the high mortality associated with its infections might
be strongly related to the potential of virulence factors
exhibited by this species, such as adhesion to different host
surfaces, biofilm formation, infection and dissemination,
and enzymes secretion. Therefore, the aim of this review is
to outline the present knowledge on all the above-
mentioned C. tropicalis virulence traits.
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Introduction
Nosocomial infections (NIs), or in other words hospital
acquired infections, are now a serious public health
problem, since these infections are among the leading
causes of morbidity and mortality, causing an increase
in hospitalization time and, consequently, high costs
associated to patient’s treatment [1, 2]. NIs have been
particularly prominent in intensive care units (ICUs),
where the incidence is two to five times higher than in
the general population of hospitalized patients [3, 4]. The
causes for the increased risk of NIs in ICUs have been
associated with increased length of stay in ICU, invasive
procedures, patients with compromised immune systems,
and multiple exposure to antibiotics [5–7]. Beyond the
hospital unit and the disease involving the patient, factors
related to the infecting organism are of major importance
to the progression of hospital acquired infections [8].
Most of the NIs are caused by microorganisms of the
normal microbiota that attack the patient in special
situations such as under immunosupression. In these
patients, considered at risk, invasive fungal infections
are often severe, with a rapid progression and difficultly to
diagnose and/or treat [1, 7].
Fungal nosocomial infections (FNIs) incidence has in-
creased significantly over recent decades. Candida species are
the most frequently isolated fungi, corresponding to approx-
imately 80% of FNIs, being the fourth responsible cause for
blood stream infections and responsible for the overwhelming
majority of urinary tract infections [7, 9, 10].
Until recently, Candida albicans was the Candida
species that received major clinical attention. However, in
parallel with the overall increase of fungal infections, it has
been observed that infections caused by non-Candida
albicans Candida (NCAC) species are emerging [7, 11,
12]. The reasons for this alteration in the pattern of Candida
species distribution has not yet been completely under-
stood, but could be attributed to the resistance of the NCAC
species to antifungal agents, which are used for relatively
long periods during hospitalisation [9, 12–14].
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Usually, Candida tropicalis is considered the first or the
second NCAC species most frequently isolated from
bloodstream (candidemia) [12, 13, 15, 16] and from urinary
tract (candiduria) [17, 18] infections. Additionally, C.
tropicalis is often found in patients admitted to ICUs,
especially in patients with cancer, requiring prolonged
catheterization, and/or receiving broad-spectrum antibiotics
[8, 12]. This species appears to display higher potential for
dissemination in the neutropenic host than C. albicans and
other NCAC species. This propensity for dissemination in
some way may explain the reported relatively high
mortality associated with C. tropicalis [15, 19, 20].
Several virulence factors seem to be responsible for C.
tropicalis infections, which present high potential for
dissemination and mortality [21]. Adhesion to host surfaces
(epithelial cells and medical devices), as well as biofilm
formation [22, 23], secretion of enzymes (proteases and
phospholipases) and haemolytic activity are considered
important factors in C. tropicalis infection [22, 24, 25].
Therefore, this article aims to review and discuss C.
tropicalis general characteristics, focusing on its microbi-
ology, epidemiology, risk factors and mainly on its
virulence factors.
Microbiology
Candida tropicalis, first known as Oidium tropicale, was
differentiated among several Candida species in 1910 by
Aldo Castellani. Meanwhile other names have been attributed
to this species, such as Monilia tropicalis, Candida vulgaris,
Mycotorula dimorpha, Candida paratropicalis and another
58 synonyms. Only in 1923, Berkhout introduced the present
name [26, 27]. Candida tropicalis is a diploid ascomycete
yeast and an opportunistic human pathogen, which colonizes
several anatomically distinct sites, including the skin [28,
29], gastrointestinal [30] and genitourinary tracts [28], and
may also be seen in the respiratory tract [29]. It can also be
recovered from the environment, particularly from surfaces
in medical settings [22, 29, 31]. Moreover, since 1960 C.
tropicalis has been recognized as responsible for serious
invasive candidosis [32, 33].
Infections caused by C. tropicalis can be acquired
endogenously, when the individual is already colonized by
the microorganism as part of the normal flora, but under
altered conditions yeasts may be translocated and spread
through the gastrointestinal tract to different anatomic sites,
causing infection [8, 12, 15]. The exogenous infection can
occur through contact of the hands of health professionals
with patients or through catheters, implantable prostheses,
as well as parenteral solutions, which were previously
contaminated [15, 22, 34, 35].
The mechanism used by the commensal C. tropicalis to
become a human pathogen is not yet clear. Moreover, C.
tropicalis infections involve a broad spectrum of invasive
diseases, affecting patients exposed to a wide variety of risk
factors [8, 36, 37]. Among the invasive infections caused
by C. tropicalis, the most common are candiduria and
candidemia [13, 15, 17, 18, 38].
Identification
Colonies of C. tropicalis are cream-colored with a slightly
mycelial border (Fig. 1a) on the routinely used Sabouraud
dextrose agar (SDA) and appear dark blue (Fig. 1b) in
CHROMagar™ Candida (CHROMagar, Paris, France) [26,
39]. Microscopically (Fig. 1c), on corn meal Tween 80 agar
at 25°C (Dalmau method), C. tropicalis shows blastoconi-
dia singly or in small groups all along graceful, long
pseudohyphae and may also produce true hyphae.
In biochemical tests (fermentation and assimilation;
Table 1), this yeast differs from the other important
Candida species by being able to ferment and to assimilate
glucose, sucrose, galactose, trehalose, and maltose, but not
lactose or rafkose [26, 40, 41].
Genetically, C. tropicalis is more similar to C. albicans,
since it contains the major repeat sequence (MRS)
Fig. 1 Candida tropicalis morphology in routine culture media. a Colonies of C. tropicalis on Sabouraud dextrose agar. b On CHROMagar™
Candida. c On corn meal Tween 80 agar at 25°C (Dalmau method)
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elements, than C. parapsilosis and C. glabrata [42]. The
discovery of MRS elements in C. tropicalis suggests that
these repeats play a similar role in karyotypic variation in
this species, although the contribution of these changes to
pathogenesis is not known [43, 44].
For molecular identification, several procedures have been
proposed to detect and differentiate Candida species in vitro,
either by DNA extraction from cultured organisms [45, 46]
or directly from clinical samples [47–49]. Methods such as
polymerase chain reaction (PCR) assay [47, 49, 50] and real-
time PCR assays [45, 51], described in Table 2, have been
successfully used to identify C. tropicalis from clinical
samples and even when this species is found in the presence
of other fungi. Nevertheless, these methodologies are not yet
standardized or readily available in most clinical laboratory
settings nor have been validated in large clinical trials.
Risk factors
In general, the risk factors involved in the development of
hospital-acquired Candida infections are associated with:
extended periods in ICUs, administration of broad-
spectrum antibiotics, patients with immunosupression,
indwelling catheters, mechanical ventilation, candiduria,
multiple sites of colonization, burns, and hemodialysis [5, 52–
54]. However, the particularities of each Candida species
may be influenced by specific risk factors. Studies have been
shown, that in opposition to C. parapsilosis, C. tropicalis
was less likely to occur among children of less than one year
of age, but more likely to occur in patients with cancer or
neutropenia [15, 55, 56], and is strongly associated with the
presence of biofilms in urinary catheters. [18, 52, 57–59].
Candida colonization remains the most universally
accepted predictive variable with regard to invasive
candidiasis, being particularly true for high density
colonization. In fact, colonization by C. tropicalis,
especially from a specific body site can be highly
predictive of the development of invasive disease with
this organism [60]. Nevertheless, it has not yet been
clarified whether colonization can be used alone to
identify high-risk patients or if it should be combined
with other variables indicating high risk [61]. According
to Paul et al. [62], many risk factors traditionally linked
to candiduria may be associated with urinary tract
infections in general. Furthermore, Binelli et al. [63]
found a significant association of candidemia with
candiduria, although urine was not the main source of
C. tropicalis bloodstream infection.
According to epidemiological data, when comparing
patients with candidemia caused by C. tropicalis to those
caused by other species of Candida, on average, the former
are older patients (67 years vs. 56 years, P=0.01), present
cancer (45.5% vs. 31.6%, P=0.04), and the portal of entry
is the abdomen (32.2% vs. 11.9%, P=0.001). Additionally,
these patients also have a high hospital mortality rate (61%
vs. 44%, P=0.03) [64]. Further studies suggested that C.
tropicalis is associated with higher dissemination potential
and mortality in patients admitted in ICU, particularly in
oncology patients, than C. albicans or any other NCAC
species [13, 15, 65].
Epidemiology
The proportion of candidosis (candidemia and candiduria)
caused by C. tropicalis varies widely with geographical
area and patient group, with C. tropicalis being more
prevalent, even compared with C. albicans, in certain
countries [64, 66, 67]. Considering Table 3, it is possible
to see that, among NCAC species, C. tropicalis has been
considered the species most frequently isolated from
candidosis in the Pacific-Asia region [13], Brazil [12, 15],
and recently in Europe [7, 68]. Furthermore, important
epidemiological studies revealed that 90% of invasive
candidosis were due to NCAC species, with C. tropicalis
accounting for about 4–6% in 1997–1998, 5.3% in 1999,
and 7.3% in 2000–2003 [69]. Additionally, in general, C.
Table 1 Microbiological and biochemical characteristics of C. tropicalis compared with other important Candida species
Candida specie Microbiology Biochemicala
Hyphae Pseudohyphae Germinative tube glu gal lac mal suc meli cel tre raf mel urease KHO3
C. tropicalis + + – FA FA – FA FA – A± FA – A – –
C. albicans + + + FA AF± – FA A – – AF± – A± – –
C. parapsilosis – + – AF± A – A AF± – – AF± – A – –
C. glabrata – – – FA – – – – – – A± – – – –
a Biochemical analyses: Fermentation and assimilation in the presence of a carbon source, such as glucose (glu), galactose (gal), lactose (lac),
maltose (mal), sucrose (suc), melibiose (meli), celobiose (cel), trehalose (tre), raffinose (raf), melezitose (mel). Urea hydrolysis (urease) and
assimilation of KHO3
+ positive, − negative, FA fermentation and assimilation positive, A assimilation positive, A± assimilation variable, AF± assimilation positive with
fermentation variable
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tropicalis appeared to be the first or second NCAC most
frequently associated to candiduria. Nevertheless, regarding
candidemia, C. tropicalis is less frequently isolated than C.
glabrata [7, 17, 52, 65, 68].
Although the reasons for the increased detection of C.
tropicalis in human infection are not completely clear, the
advent of molecular genetics and the development of new
methods of Candida identification and differentiation [45,
47, 70] may play an important role. Further, the changes of
C. tropicalis incidence may also be attributed to the greater
use of fluconazole nowadays [64, 67]. In the United States,
due to fluconazole prophylaxis the frequency of candidosis
caused by C. tropicalis has decreased. However, in other
countries where it is not usual to use fluconazole
prophylaxis, C. tropicalis appears more prevalent, e.g.
second in Latin America, and even more common than C.
Table 2 Primers and probes used for polymerase chain reaction (PCR) and real-time PCR assay used for the identification of C. tropicalis from
clinical samples and when this species is found in the presence of other fungi
Molecular method (reference) Sequence (direction) Description
PCR-based [47] C. tropicalis I Primer mixes specific to Candida DNA topoisomerase II
genes.(F) 5′-GTTGTACAAGCAGACATGGACTG-3′
(R) 5′-CAAGGTGCCGTCTTCGGCTAAT-3′
(R) 5′-TCAAGGTACAGTTATGGCCAAGTT-3′
C. tropicalis II
(F) 5′-CTGGGAAATTATATAAGCAAGTT-3′
For the identification of Candida tropicalis to the species
level, one species-specific forward primer and two
species-specific reverse primers were designed within
the region amplified by the degenerated primer pair
(R) 5′-CTTGAGATACTCAATCTTTTATC-3′
(R) 5′-TCAATGTACAATTATGACCGAGTT-3′
Multiplex PCR [50, 114] ITS1 5′-TCC GTA GGT GAA CCT GCG G-3′ The method is based on the size variability of the ITS1
region in different species.The fungi-specific primers
ITS1 and ITS2 are used to amplify a small conserved
portion of the 18S rDNA region, the adjacent ITS1, and
a small portion of the 28S rDNA region, generating
different PCR products for C. glabrata, C. guilliermondii,
C. lusitaniae, C. parapsilosis, C. tropicalis and C. krusei
ITS2 5′-GCT GCG TTC TTC ATC GAT CG-3′
PCR and pyrosequencing
[49]
PCR: The tests are performed on amplicons derived from the 18S
rRNA gene using PCR universal primers for amplification.
The amplification products were subjected to
pyrosequencing
analysis—a method f DNA sequencing (determining the
order of nucleotides in DNA) based on the "sequencing by
synthesis" principle
bio-fun (F) 5′-Biotin-ATTGGAGGGCAAGTCT
GGTG-3′
fun (R) 5′-CCGATCCCTAGTCGGCAT-3′
Pyrosequencing:
funS 5′-YTCAMAGTAAAAGTCCTGG-3′ or
funS2 5′-TCAAAGTAAAAGTCCTGGTTC-3′
C. tropicalis pyrosequencing with primers funS
or funS2:
TTCGCCAAAAGGCTAGCCAGAAGGAAAG
GCTCGGTTGGGTC
LightCycler PCR [45, 92] Primer The LightCycler PCR combines rapid amplification of nucleic
acids in glass capillary with melting curve analysis based
on fluorescence resonance energy transfer for the sensitive
detection of point mutations in various settings. Species-
specific amplification (standard PCR) and hybridization
(LightCycler PCR) of Candida DNA could be achieved
using the species-specific primer pairs and the
oligonucleotides, respectively
CTR-PR (F) 5′-TCATACCAGTGATAGATGG-3′
CTR-PR (R) 5′-TTTTCTAGCTACTCCATGG-3′
Probes
CTR-FL 5′-GTTGATTACCAATCCATGGTTA
CCTTAC-3′
CTR-RED 5′-ATTAGAACCTGCTGAAATTG
TTTGG-3′
Real-time PCR assays [48] Candida-specific primers The application of the biprobe technology facilitated a rapid
screening for fungi (specific for the fungal ITS2 region) and
simultaneous differentiation of 11 medically important
Aspergillus and Candida species (with species-specific
biprobes) in only two individual PCR mixtures and
simultaneously in the same LightCycler run
Cand (F) CCTGTTTGAGCGTCRTTT
ITS (R) TCCTCCGCTTATTGATAT
Candida-specific probes
C.trop-S Cy5-GGCCACCACAATTTATTT
CA-biotin
(F) and (R) indicate forward and reverse primers, respectively
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glabrata in the Asia-Pacific region [69]. Nevertheless, the
use of prophylactic fluconazole can become a risk factor
since some cross-resistance between azoles [7, 11, 71] has
been reported already. Several studies indicate that C.
tropicalis has been showing a moderate level of fluconazole
tolerance leading to the need of an increase in the drug
concentrations and enabling a risk of azole resistance [65,
72, 73].
Curiously, according to Table 3, the epidemiological data
related to antifungal resistance have been indicating an
Table 3 Summary of incidence and antifungal resistance attributed to Candida tropicalis candidosis (candidemia and candiduria)
Candidosis References Region/Country (period) Number of strains C. tropicalis (%) Other NCAC
speciesa (%)
Resistance (%)
Candidemia [115] Kuwait (1996–2005) 607 12.4 36.2 Flu (0)
Itra (0)
Vor (0·5)
5Flu (9·3)
[116] Europe (1997–1999) 2089 7 44 ND
[75] Italy (2000–2003) 94 16.0 35.1 Flu (0)
Itra (0)
Vor (0·5)
5Flu (3)
[15] Brazil (2003–2006) 924 20 20 Flu (6·6)
Itra (6·6)
Vor (0·5)
5Flu (20)
Pos (6·6)
[12] Brazil (2003–2004) 712 20.9 25.4 Flu (0)
Itra (0)
Vor (0)
5Flu (5)
[13] India (2007) 140 42.1 6.4 Flu (10·2)
Itra (13·6)
Vor (10·2)
Cas (2)
[117] Europe/Asia/America
(2008–2009)
1239 9.8 34.8 Flu (3·3)
Vor (3·3)
Pos (0·8)
Cas (0)
Candiduria [18] USA (1991–1993) 530 7.9 19.7 ND
[17] Spain (1998–1999) 389 36 8.2 ND
[63] Brazil (1996–2000) 23 43.5 4.3 ND
[118] Slovakia 94 6.3 24.7 ND
[52]b France (2001–2002) 233 6.5 30.5 Flu (0)
Itra (0)
Vor (0)
5Flu (59)
Cas (8·7)
[68] Portugal (2003–2006) 260 12.7 12.3 ND
[73] Brazil (2006–2007) 70 15.7 18.5 Flu (0)
Itra (18·1)
Flu Fluconazole, Itra Itraconazole, Vor Voriconazole, 5Flu 5-Flucytosine, Pos Posoconazole, Cas Caspofungin, ND not determined
a Percentage of Candida glabrata and/or Candida parapsilosis
b In vitro susceptibilities of 22C. tropicalis bloodstream and urine isolates
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increase of C. tropicalis resistance to 5-flucytosine [12, 15,
52, 74, 75]. Furthermore, it was observed 35% of resistance
to 5-flucytosine by C. tropicalis isolates recovered from
blood cultures in the active surveillance program on yeast-
related fungemia implemented by the French National
Reference Center for Mycoses and Antifungals (NRCMA)
in the Paris area [74]. Additionally, Densos-Olliver et al.
[74] studied the relationship between epidemiologic and
genomic data of C. tropicalis 5-flucytosine resistance, and
they observed that a clone of 5-flucytosine-resistant
isolate, associated with malignancies, had lower mortality
than the other C. tropicalis isolates. This suggests that
geographic and temporal distribution of C. topicalis may
be related with 5-flucytosine-resistant isolates in the Paris
area.
In fact, the major problem with the development of
invasive candidosis by C. tropicalis is that it is associated
with higher mortality than other NCAC species and C.
albicans [8, 20, 66, 76]. This propensity of C. tropicalis for
dissemination and associated high mortality may be related
to the virulence factors exhibited by this species such as
biofilm formation, proteinases secretion and dissemination
[11, 22].
Virulence factors
Mechanisms used by Candida species with the purpose of
causing any type of injury to the host are related to
virulence factors. Several mechanisms of pathogenicity
have been associated with C. tropicalis, such as adhesion
to different surfaces (Fig. 2), biofilm formation, capacity of
dissemination (Fig. 3), and hyphae and enzymes produc-
tion. These factors are concisely described in Table 4.
Additionally, relevant findings indicate higher pathogenic-
ity for C. tropicalis than other NCAC species. Unfortu-
nately, the pathogenic mechanisms of C. tropicalis have not
been yet fully elucidated [20, 21, 64, 65, 77].
Adhesion and biofilm formation
Candida tropicalis possesses a remarkable capacity to
adhere to abiotic surfaces, human cells and tissues. It
is known that Candida cells have several different
adhesins (special cell wall proteins), which allows
adhesion to specific substrates. Candida Als (aggluti-
nin-like sequence) is considered an important protein
family during the process of adhesion, mediating attach-
ment to different epithelium cells, functioning as an
adhesin. Furthermore, southern blot analysis with ALS-
specific probes suggested the presence of ALS gene
families in C. tropicalis [78, 79]. Furthermore, other
factors, such as physicochemical interactions between
yeast cells and materials surface, as well as environmen-
tal factors, can influence the initial adhesion of C.
tropicalis [21, 80–82]. Several studies showed the ability
of C. tropicalis to adhere, and consequently to form
biofilms, in clinically relevant substrates like medical
devices, and in different environmental situations, both in
vitro and in vivo. Adherence of Candida cells to abiotic
surfaces and to other cells is vital for biofilm formation
[80, 82–85].
Candida biofilm formation is initiated when the yeast
adheres to a surface, cells attach to each other and begin to
proliferate—ultimately leading to the formation of a highly
structured mature biofilm, comprised of complex intertwin-
ing layers of yeast, pseudohyphae and hyphae embedded in
the extracellular matrix [86, 87]. The matrix is one of the
most distinctive features of a microbial biofilm. This
complex extracellular material might function to defend
against phagocytic cells, to serve as a scaffold for
maintaining biofilm integrity, and to limit diffusion of toxic
substances into the biofilm, as antifungals [86, 88]. Further,
studies indicate that C. tropicalis biofilms exhibit large
amounts of matrix material completely resistant to anti-
fungals [23, 65, 89–91]. Those data can explain why the
Fig. 2 Candida tropicalis adhered to different surfaces. a Optical
micrograph of C. tropicalis on silicone coupons. b Scanning electron
micrograph of C. tropicalis adhered to a human epithelial urinary
bladder cell line. c Confocal laser scanning microscopy image of C.
tropicalis adhered to a reconstituted human oral epithelium
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major risk factor of C. tropicalis in candidose development
is related to the difficulty of treatment and, moreover, to the
prolonged catheterization [64, 71, 92].
In a study done by Al-Fattani and Douglas [89], it was
shown that the matrix of C. tropicalis contained carbohy-
drates, proteins, hexosamine, phosphorus and uronic acid.
The major component in C. tropicalis matrix was hexos-
amine (27%), whereas in C. albicans matrix it was glucose
(32%). It is important to emphasize that hexosamine is
present in Streptococcus epidermidis as a polysaccharide,
which is sometimes referred to as the intercellular polysac-
charide adhesin (PIA) and is known to mediate cell–cell
interaction within the biofilm [93]. Further, in the same
study, biofilms of C. albicans were more easily detached
from plastic surfaces by treatment with the enzyme lyticase
than were those of C. tropicalis.
However, C. tropicalis biofilm and consequently matrix
composition are extremely dependent on environmental
conditions, such as medium composition, pH, oxygen and
growth conditions (static or flow) [82, 84, 90]. According
to a study by Jain et al. [59] comparing Candida biofilms
grown in RPMI medium and artificial urine, biofilm
formation is highly dependent on the growth medium. In
particular, C. albicans strains produced more biofilm in
artificial urine than in RPMI. Furthermore, other
researches indicated that biofilms grown under conditions
of continuous flow produced more matrix than those
grown statically, and were significantly more resistant to
amphotericin B [89].
Another important factor about the biofilm life cycle is
related to dispersion/detachment or dissolution of cells,
which release from the biofilm and seed new surfaces with
the consequent establishment of disseminated candidiasis at
distal organs. Additionally, there are indications that
dispersed cells from biofilms are more virulent than
planktonic cells [86]. Negri et al. [84] detected that C.
tropicalis cells are able to detach from biofilms formed in
catheters under a flow of artificial urine and move upflow.
However, little is still known about C. tropicalis detach-
ment cells from biofilms and more studies are necessary to
better understand this process.
Infection and dissemination
Adherence of C. tropicalis to host cells, and consequently
colonization, is seen as an essential early step in the
establishment of disease, since high density colonization is
indicative of high risk factor to the host [61, 64]. It is
known that C. tropicalis is able to adhere, colonize and
infect host tissues and further disseminate, both in vivo and
in vitro [21, 22, 81, 83].
It is interesting to observe that, according to some
researchers, C. tropicalis strains showed intermediate levels
of adherence to buccal epithelial cells [30, 83] and to
human epithelial cell monolayers [94], whereas C. albicans
strains showed high in vitro adherence. However, in other
studies, C. tropicalis showed similar or higher extent of
adhesion than C. albicans when in contact with human
epithelial cell monolayers [95] and endothelium from
porcine vascular tissues [96]. Therefore, it is possible to
verify that Candida species do not adhere in the same
manner to the different mucosal types of cells, and also that
there is distinct interaction between epithelium morphology
and molecular events during Candida adhesion [97].
In a recent in vivo experimental study in mice, Okawa et
al. [98] observed that the pathogenicity of C. tropicalis
strains was not correlated with the adherence ability. Silva et
al. [81] recently demonstrated that only filamentous forms of
C. tropicalis were able to invade an oral epithelium
reconstituted model. In fact, hyphae have an important
role in tissue invasion, and in vitro research has shown
that C. albicans lacking hyphal formation exhibited lower
ability for tissue invasion compared with wild-type C.
albicans strains [99]. The morphological forms exhibited
by C. tropicalis are similar to those shown by C. albicans,
but despite these few studies, there is no more evidence on
the importance of C. tropicalis morphology in virulence.
Furthermore, these studies indicate that after prolonged
infection C. tropicalis increases its infectivity, causing
more tissue damage and mice mortality [21, 81, 99].
Corroborating this fact, C. tropicalis was found to be
highly invasive after 12 h of infection, with extensive
tissue damage occurring after 24 h [81].
Thus, the pathogenic mechanisms of C. tropicalis seem
to be different from those of C. albicans [21, 95]. A
significant work [100] on pathogenicity of Candida species
in an animal model showed that the most pathogenic group
was C. albicans and C. tropicalis, followed by an
intermediate group with C. glabrata, C. lusitaniae and C.
kefyr and a least pathogenic group of C. parapsilosis, C.
Fig. 3 Confocal laser scanning micrograph of C. tropicalis infecting
reconstituted human oral epithelium
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Table 4 Candida tropicalis virulence factors analysed and major conclusions
Reference Virulence factor Candida sp. (n) Comments
[96] Adhesion to biotic surface and
infection
C. tropicalis (1); C. albicans (1);
C. parapsilosis (1); C. glabrata (1);
C. krusei (1); C. pseudotropicalis (1)
Candida interaction with endothelium using porcine whole
blood vessel. C. albicans and C. tropicalis adhered in a
higher extent followed by C. krusei, C. parapsilosis, C.
pseudotropicalis, and C. glabrata
[30] Adhesion to a biotic surface C. glabrata (12); C. lusitaniae (1);
C. kefyr (1); C. krusei (2); C.
colliculosa (1); C. parapsilosis (2);
C. tropicalis (2); C. albicans (12);
This work studied the adherence of different Candida strains
isolated from the human gastrointestinal tract. Adherence to
buccal epithelial cells was maximal for C. albicans, C.
tropicalis and C. parapsilosis and minimal for C. krusei
[21] Adhesion to a biotic surface;
dissemination in vivo;
hydrophobicity; acidic conditions;
sucrose assimilation
C. tropicalis (5); C. albicans (1) C. tropicalis strains were tested for their lethality in mice,
adherence to Hela cells, hydrophobicity, yeast growth
under acidic conditions (pH 2.0–5.9) and sucrose
assimilation. The pathogenicity in mice by all the tested
C. tropicalis strains was not correlated with the
adherence, the hydrophobicity, or yeast growth. The
pathogenicity correlated well with the sucrose
assimilation ability. Pathogenic mechanisms of
C. tropicalis strains were different from those of the
C. albicans assayed
[81] Infection to epithelium; enzyme
expression
C. tropicalis (6) This study investigated the infectivity of C. tropicalis
isolates using a reconstituted human oral epithelium
(RHOE) and secreted aspartyl proteinase (SAPT) gene
expression. SAPT1-4 genes expression was strain-
dependent, with SAPT2-4 transcripts being frequently
detected and SAPT1 rarely detected. C. tropicalis was
highly invasive with the ability to induce significant
tissue damage. These features, however, do not appear to
be related to specific SAPT gene expression
[80] Adhesion and biofilm formation
to abiotic surface; Candida
surface properties
C. tropicalis (2); C. parapsilosis (2);
C. glabrata (2)
This work compared both the adhesion and biofilm
formation on silicone of urinary clinical isolates in the
presence of urine. NCAC species were able to adhere to
and survive on silicone in the presence of urine. Similar
water contact angle values were obtained for all NCAC
strains. C. glabrata strains presented higher colonization
abilities than C. tropicalis and C. parapsilosis strains
[89] Biofilm and drug resistance C. tropicalis (1); C. albicans (1) In this study, the chemical matrix composition of C.
albicans and C. tropicalis biofilms and biofilm drug
resistance were analysed. C. tropicalis biofilm matrix
contained carbohydrates, proteins, hexosamine,
phosphorus and uronic acid, but its major component was
hexosamine, whereas in C. albicans matrix the major
component was glucose. Biofilms of C. tropicalis
synthesized large amounts of matrix material and such
biofilms were completely resistant to both amphotericin B
and fluconazole
[23] Biofilm and drug resistance C. tropicalis (2) This study investigated the characteristics of C. tropicalis
biofilm development regarding the different growth phases,
morphology and antifungal susceptibility. Mature biofilms
consisted of a dense network of yeast cells and filamentous
forms of C. tropicalis. Increased resistance of sessile cells
against fluconazole and amphotericin B was detected.
Sessile cells overexpressed ERG11 and MDR1 by real-
time PCR, indicating fluconazole resistance by C.
tropicalis biofilm
[110] Haemolyse activity C. tropicalis (5); C. albicans (15);
C. dubliniensis (2); C. glabrata (34);
C. parapsilosis (5); C. lusitaniae (2);
C. famata (3); C. guilliermondii (4);
C. rugosa (1); C. utilis (1); C.
pelliculosa (1); C. kefyr (2); C. krusei
(4); C. zeylanoides (1)
This is the first study demonstrating the variable expression
profiles of haemolysins by different Candida species. Total
and partial hemolysis was detectable in C. albicans, C.
dubliniensis, C. kefyr, C. krusei, C. zeylanoides, C.
glabrata, C. tropicalis, and C. lusitaniae. Only partial-
hemolysis was detectable in C. famata, C. guilliermondii,
C. rugosa, and C. utilis. No hemolytic activity was
observed in C. parapsilosis and C. pelliculosa
[108] Ezymes production and biofilm;
susceptibility testing
C. tropicalis (6); C. albicans (2);
C. glabrata (5); C. krusei (3);
Candida sp. (2)
The production of acid protease, phospholipase, haemolysin,
and biofilm formation was evaluated. One isolate of C.
tropicalis had a strong positive phospholipase activity and
high resistance to fluconazole. All isolates showed
hemolytic activity
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krusei and C. guillerimondii. It is important to emphasize
the clinical relevance of those findings, since the major
problems with the development of invasive C. tropicalis
candidosis are associated with high dissemination and
mortality.
Enzymes production
Once adhered to host cells, C. tropicalis requires other
factors to penetrate into the deepest tissues, e.g., hyphal
formation and production of enzymes. In fact, the patho-
genic capabilities of this yeast have been related to the
secretion of aspartyl proteinases, phospholipases and
haemolytic activity [22, 24, 25, 65, 79, 101].
Candida produce a large variety of secreted hydrolases,
and among the various potential virulence factors proposed,
the secreted aspartyl proteinases (Sap) have been intensive-
ly investigated. It is now well established that the ability of
C. albicans to adhere to mucosae, to invade in deep organs,
and to resist to phagocytic cells, apparently requires the use
of several different proteinases suitable to each particular
condition during the infection. Like C. albicans, C.
tropicalis presents in vitro Sap activity in a medium
containing bovine serum albumin (BSA) as the sole source
of nitrogen [22, 31, 79, 102].
Furthermore, Zaugg et al. [24] characterized a total of
four SAPT gene families of C. tropicalis. According to this
study, RT-PCR experiments revealed a strong SAPT1 signal
with RNA extracted from cells grown in BSA medium. The
SAPT2 and SAPT3 gene products, Sapt2p and Sapt3p,
which have not yet been detected in C. tropicalis cultures in
vitro, were produced as active recombinant enzymes with
the methylotrophic yeast Pichia pastoris as an expression
system. However, a weak signal was obtained with all other
SAPT genes under in vitro conditions tested, suggesting that
the gene products Sapt2p, Sapt3p, and Sapt4p could be
produced during infection.
This idea is highlighted by recent studies [81, 99] that
investigated epithelial infection by C. tropicalis using a
reconstituted human oral epithelium (RHOE) and SAPT
gene expression. The results obtained by real-time PCR
showed that C. tropicalis isolates were able to express
Table 4 (continued)
Reference Virulence factor Candida sp. (n) Comments
[104] Enzymes production C. tropicalis (9); C. albicans (60);
C. glabrata (4); C. parapsilosis (2);
C. lusitaniae (1); C. famata (3);
C. guilliermondii (3); C. rugosa (2);
C. kefyr (4); C. krusei (6); C.
lipolytica (4)
Phospholipase and protease activities were tested in clinical
Candida isolates with reference to the sources of strains.
Protease producers in NCAC species were observed as C.
kefyr, C. lipolytica, C. parapsilosis and C. tropicalis.
Candida albicans isolates tested were phospholipase
producers and only a few strains of C. glabrata and C. kefyr
behaved in the same way. The quantity of phospholipase
produced by C. albicans varied with the specific isolate
and correlation with the site of infection
[107] Enzymes production C. tropicalis (19); C. albicans (77) Candida albicans and C. tropicalis were obtained from whole
saliva of patients presenting signs of oral candidosis.
Proteinase activity was observed in both C. albicans and C.
tropicalis, but phospholipase activity was only noted in
C. albicans. In vitro resistance to antifungals was verified in
both species, but C. tropicalis appears to be more resistant to
the tested antifungals than C. albicans
[113] Enzymes production C. tropicalis (11); C. albicans (24);
C. glabrata (22); C. krusei (5)
The aim was to determine the enzymatic activity and to
investigate the distribution of phospholipase C gene
of several Candida isolates from patients with pulmonary
tuberculosis and non tuberculosis patients. Phospholipase
activity from C. albicans, C. tropicalis and C. krusei
exhibited some similarity in both groups. Candida isolates
invariably showed high levels of phospholipase, proteinase,
caseinase and lipase activities
[22] Adhesion to abiotic surface and
biofilm formation; adhesion to
biotic surface; hyphae formation;
enzymes production; susceptibility
testing
C. tropicalis (7) Characterization of C. tropicalis virulence and antifungal
susceptibility. All clinical isolates presented one or more
virulence factors. Candida tropicalis strains adhered
significantly more to epithelium than to silicone. All strains
were able to form biofilms and to express total haemolytic
activity. However, protease was only produced by two
isolates. Only one strain was phospholipase positive. Four
strains were susceptible-dose dependent to itraconazole and
one clinical isolate was found to be resistant. It was not
possible to establish a relation among the virulence factors
assayed
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SAPT1-4 during the infection process. Moreover, expres-
sion was strain-dependent, with SAPT2-4 transcripts being
frequently detected and SAPT1 rarely detected. Further-
more, C. tropicalis can be considered as highly invasive
with the ability to induce significant tissue damage [81].
These features, however, do not appear to be related to
specific SAPT gene expression. Therefore it is necessary to
perform more investigations focusing on SAPT gene
families of C. tropicalis for better understanding the
specific role of these genes.
In addition to Saps, enzymes categorized as lipases
(LIPs), i.e., enzymes that hydrolyze phospholipids into
fatty acids, are often considered to be involved in C.
tropicalis pathogenicity and are suggested to contribute to
host cell membrane damage which could also expose
receptors to facilitate adherence [101, 103, 104]. In C.
albicans, ten genes encoding for LIPs (LIP1-10) have
been identified and similar sequences were also detected
in C. tropicalis [105]. Nevertheless, the most widely used
diagnostic method for phospholipases (PLs) determination
is based on yeast growth in an egg yolk agar medium
[106]. According to recent studies, using this method, C.
tropicalis, from different sources, appears to have a
reduced ability to produce extracellular PLs in vitro when
compared to C. albicans [29, 104, 107]. However, this
production is highly species and strain dependent [22, 25,
108, 109].
Other important virulence factor recently described in
literature is related with haemolytic activity which is tested
on sheep blood agar supplemented with glucose [110]. It is
known that enzymes as haemolysins are used by
Candida species to degrade haemoglobin and facilitate
recovery of the elemental iron from host cells, which is a
contribution to pathogenicity in Candida species. Thus,
haemolysins are considered key virulence factors en-
abling pathogen survival and persistence in the host
[110–112]. The studies reported so far show that C.
tropicalis are all able to produce haemolysins in vitro,
inducing partial or total erythrocyte lyses, although the
degree is strain dependent [110]. According to Luo et al.
[110], total-haemolytic activities in C. albicans and C.
tropicalis were significantly higher than in C. glabrata.
However, Kumar et al. [113] observed the opposite, C.
glabrata displayed the highest haemolytic activity when
compared with C. albicans and C. tropicalis. Although
significant studies showed the ability of C. tropicalis to
produce haemolytic activity on sheep blood agar supple-
mented with glucose, it is important to assess whether the
haemolytic activity observed is true or is a product of
extracellular PLs of Candida species. Moreover, it is still
necessary to have more advances in molecular studies to
clarify the role of haemolytic activity in C. tropicalis
pathogenesis.
Concluding remarks
In fact, the frequency of Candida tropicalis causing
candidosis has been increasing in recent decades, probably
due to several situations, e.g., new and efficient molecular
methods of identification; antifungal resistance, mainly to
fluconazole commonly used as prophylaxis agent; and
factors related with host as well as invasiveness surgery,
long periods in ICU, antibiotic administration and catheter-
ization. Additionally, invasive disease developed by C.
tropicalis is associated with colonization, high potential of
dissemination and pathogenicity by this organism. This is
mainly because C. tropicalis possesses a diversity of
virulence factors that induce serious damage to patients
and increases the mortality risk. However, much more
research is necessary to get deeper insights into the
strategies used by C. tropicalis to change from a harmless
commensal microorganism to become a human pathogen of
high clinical concern.
Acknowledgments The authors acknowledge Coordenação de
Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil,
for supporting Melyssa Negri (BEX 4642/06-6) and Fundação
para a Ciência e Tecnologia (FCT), Portugal, for supporting
Sonia Silva (SFRH/BPD/71076/2010), and European Community
fund FEDER, trough Program COMPETE under the Project
FCOMP-01-0124-FEDER-007025 (PTDC/AMB/68393/2006) is
gratefully acknowledged.
Conflicts of interest None declared.
References
1. Hota B (2004) Contamination, disinfection, and cross coloniza-
tion: are hospital surfaces reservoirs for nosocomial infection?
Clin Infect Dis 39(8):1182–1189. doi:10.1086/424667
2. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer
S, Herwaldt L, Pfaller M, Diekema D (2003) Attributable
mortality of nosocomial candidemia, revisited. Clin Infect Dis
37(9):1172–1177. doi:10.1086/378745
3. Bassetti M, Righi E, Costa A, Fasce R, Molinari M, Rosso R,
Pallavicini F, Viscoli C (2006) Epidemiological trends in
nosocomial candidemia in intensive care. BMC Infect Dis 6
(1):21. doi:10.1186/1471-2334-6-21
4. ChengM-F, Yang Y-L, Yao T-J, Lin C-Y, Liu J-S, Tang R-B, Yu K-
W, Fan Y-H, Hsieh K-S, HoM, Lo H-J (2005) Risk factors for fatal
candidemia caused by Candida albicans and non-albicans Candi-
da species. BMC Infect Dis 5(1):22. doi:10.1186/1471-2334-5-22
5. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas
ME (2008) Candida albicans versus non-albicans intensive care
unit-acquired bloodstream infections: differences in risk factors
and outcome. Anesth Analg 106(2):523–529. doi:10.1213/
ane.0b013e3181607262
6. Meric M, Willke A, Caglayan C, Toker K (2005) Intensive care
unit-acquired infections: incidence, risk factors and associated
mortality in a Turkish university hospital. Jpn J Infect Dis 58
(5):297–302
1408 Eur J Clin Microbiol Infect Dis (2012) 31:1399–1412
7. Lass-Flörl C (2009) The changing face of epidemiology of
invasive fungal disease in Europe. Mycoses 52(3):197–205.
doi:10.1111/j.1439-0507.2009.01691.x
8. Eggimann P, Garbino J, Pittet D (2003) Epidemiology of
Candida species infec t ions in cr i t ica l ly i l l non-
immunosuppressed patients. Lancet Infect Dis 3(11):685–702.
doi:10.j.clp.2007.1/S1473-3099(03)00801-6
9. Snydman DR (2003) Shifting patterns in the epidemiology of
nosocomial Candida infections. Chest 123(5 Suppl):500S–503S.
doi:10.1378/chest.123.5_suppl.500S
10. Lundstrom T, Sobel J (2001) Nosocomial Candiduria: a review.
Clin Infect Dis 32(11):1602–1607. doi:10.1086/320531
11. Krcmery V, Barnes AJ (2002) Non-albicans Candida spp.
causing fungaemia: pathogenicity and antifungal resistance. J
Hosp Infect 50(4):243–260. doi:10.1053/jhin.2001.1151
12. Colombo AL, Nucci M, Park BJ, Nouer SA, Arthington-Skaggs
B, da Matta DA, Warnock D, Morgan J, for the Brazilian
Network Candidemia S (2006) Epidemiology of Candidemia in
Brazil: a nationwide sentinel surveillance of Candidemia in
eleven medical centers. J Clin Microbiol 44(8):2816–2823.
doi:10.1128/jcm.00773-06
13. Chakrabarti A, Chatterjee SS, Rao KLN, Zameer MM, Shivap-
rakash MR, Singhi S, Singh R, Varma SC (2009) Recent
experience with fungaemia: change in species distribution and
azole resistance. Scand J Infect Dis 41(4):275–284. doi:10.1080/
00365540902777105
14. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC,
Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R,
the EWGoC (2004) Epidemiology of Candidaemia in Europe:
results of 28-Month European Confederation of Medical Mycology
(ECMM) hospital-based surveillance study. Eur J Clin Microbiol
Infect Dis 23(4):317–322. doi:10.1007/s10096-004-1103-y
15. Nucci M, Colombo AL (2007) Candidemia due to Candida
tropicalis: clinical, epidemiologic, and microbiologic character-
istics of 188 episodes occurring in tertiary care hospitals. Diagn
Microbiol Infect Dis 58(1):77–82. doi:10.j.clp.2007.1/j.diagmi
crobio.2006.11.009
16. Hsueh P-R, Graybill JR, Playford EG, Watcharananan SP, Oh M-
D, Já alam K, Huang S, Nangia V, Kurup A, Padiglione AA
(2009) Consensus statement on the management of invasive
candidiasis in intensive care units in the Asia-Pacific Region. Int
J Antimicro Ag 34(3):205–209. doi:10.j.clp.2007.1/j.ijantimi
cag.2009.03.014, 34
17. Álvarez-Lerma F, Nolla-Salas J, León C, Palomar M, Jordá R,
Carrasco N, Bobillo F (2003) Candiduria in critically ill patients
admitted to intensive care medical units. Intensive Care Med 29
(7):1069–1076. doi:10.1007/s00134-003-1807-y
18. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS,
Karchmer AW, Sugar AM, Sharkey PK, Wise GJ, Mangi R,
Mosher A, Lee JY, Dismukes WE (2000) Prospective multicen-
ter surveillance study of funguria in hospitalized patients. Clin
Infect Dis 30(1):14–18. doi:10.1086/313583
19. Krcmery VJ (1999) Candidemia in cancer patients: Risk factors
and outcome in 140 episodes from a single cancer institution.
Acta Chemoth 5:133–145
20. Kontoyiannis Dimitrios P, Vaziri I, Hanna Hend A, Boktour M,
Thornby J, Hachem R, Bodey Gerald P, Raad Issam I (2001)
Risk factors for Candida tropicalis fungemia in patients with
cancer. Clin Infect Dis 33(10):1676–1681. doi:10.1086/323812
21. Okawa Y, Miyauchi M, Kobayashi H (2008) Comparison of
pathogenicity of various Candida tropicalis strains. Biol Pharm
Bull 31(8):1507–1510. doi:10.1248/bpb.31.1507
22. Negri M, Martins M, Henriques M, Svidzinski T, Azeredo J,
Oliveira R (2010) Examination of potential virulence factors of
Candida tropicalis clinical isolates from hospitalized patients.
Mycopathologia 169(3):175–182. doi:10.1007/s11046-009-9246-0
23. Bizerra FC, Nakamura CV, de Poersch C, Svidzinski TIE,
Quesada RMB, Goldenberg S, Krieger MA, Yamada-Ogatta SF
(2008) Characteristics of biofilm formation by Candida tropica-
lis and antifungal resistance. FEMS Yeast Res 8(3):442–450.
doi:10.1111/j.1567-1364.2007.00347.x
24. Zaugg C, Borg-von Zepelin M, Reichard U, Sanglard D, Monod M
(2001) Secreted aspartic proteinase family of Candida tropicalis.
Infect Immun 69(1):405–412. doi:10.1128/iai.69.1.405-412.2001
25. Galan-Ladero MA, Blanco MT, Sacristan B, Fernandez-
Calderan MC, Perez-Giraldo C, Gomez-Garcia AC (2010)
Enzymatic activities of Candida tropicalis isolated from
hospi ta l ized pat ien ts . Med Mycol 48(1) :207–210.
doi:10.1080/13693780902801242
26. Larone D (2002) Medically important fungi; a guide to
identification, 4th edn. ASM Press, Washington
27. Kurtzman CP, Fell JW (1998) The yeasts, a taxonomic study, 4th
edn. Elsevier Science Ltd, New York
28. Basu S, Gugnani H, Joshi S, Gupta N (2003) Distribution of
Candida species in different clinical sources in Delhi, India, and
proteinase and phospholipase activity of Candida albicans
isolates. Rev Iberoam Micol 20(4):137–140
29. Oksuz S, Sahin I, Yildirim M, Gulcan A, Yavuz T, Kaya D, Koc
A (2007) Phospholipase and proteinase activities in different
Candida species isolated from anatomically distinct sites of
healthy adults. Jpn J Infect Dis 60(5):280–283
30. Biasoli MS, Tosello ME, Bottai H, Cuesta C, Magaró HM
(2002) Adherence of Candida strains isolated from the human
gastrointestinal tract. Mycoses 45(11–12):465–469. doi:10.1046/
j.1439-0507.2002.00793.x
31. Tamura NK, Negri MFN, Bonassoli LA, Svidzinski TIE (2007)
Fatores de virulência de Candida spp isoladas de cateteres
venosos e mãos de servidores hospitalares. Rev Soc Bras Med
Trop 40(1):91–93. doi:10.1590/S0037-86822007000100021
32. Shurtleff DB, Peterson W, Sherris JC (1963) Systemic Candida
tropicalis infection treated with amphotericin. N Engl J Med
269:1112–1115. doi:10.1056/NEJM196311212692102
33. HO D (1960) The pathogenicity of Candida tropicalis. Can Med
Assoc J 83(27):1439–1440
34. Nucci M, Silveira M, Spector N, Silveira F, Velasco E, Martins
C, Derossi A, Colombo A, Pulcheri W (1998) Fungemia in
cancer patients in Brazil: Predominance of non-albicans species.
Mycopathologia 141(2):65–68. doi:10.1023/A:1006951619245
35. Rho J, Shin J, Song J, Park M, Kee S, Jang S, Park Y, Suh S,
Ryang D (2004) Molecular investigation of two consecutive
nosocomial clusters of Candida tropicalis candiduria using
pulsed-field gel electrophoresis. J Microbiol 42(2):80–86
36. Kliemann DA, Pasqualotto AC, Falavigna M, Giaretta T, Severo
LC (2008) Candida esophagitis: species distribution and risk
factors for infection. Rev Inst Med Trop Sao Paulo 50:261–263.
doi:10.1590/S0036-46652008000500002
37. Silva EHd, Ruiz LdS, Matsumoto FE, Auler ME, Giudice MC,
Moreira D, Szeszs W, Paula CR (2007) Candiduria in a public
hospital of São Paulo (1999–2004): characteristics of the yeast
isolates. Rev Inst Med Trop Sao Paulo 49(6):349–353.
doi:10.1590/S0036-46652007000600003
38. Silva EH, Ruiz LS, Matsumoto FE, Auler ME, Giudice MC,
Moreira D, Szeszs W, Paula CR (2007) Candiduria in a public
hospital of São Paulo (1999–2004): characteristics of the yeast
isolates. Rev Inst Med Trop Sao Paulo 49(6):349–353.
doi:10.1590/S0036-46652007000600003
39. Calderone RA (2002) Introduction and historical perspectives. In:
Calderone R (ed) Candida and candidiasis. ASM Press,Washington
D.C., pp 15–25
40. Yoshio O, Kouji G (2006) Antigenicity of Candida tropicalis
strain cells cultured at 27 and 37°C. FEMS Immunol Med
Microbiol 46(3):438–443
Eur J Clin Microbiol Infect Dis (2012) 31:1399–1412 1409
41. Martin MV (1979) Germ-tube formation by oral strains of Candida
tropicalis. J Med Microbiol 12(2):187–194. doi:10.1099/
00222615-12-2-187
42. Butler G, Rasmussen MD, Lin MF, Santos MAS, Sakthiku-
mar S, Munro CA, Rheinbay E, Grabherr M, Forche A,
Reedy JL, Agrafioti I, Arnaud MB, Bates S, Brown AJP,
Brunke S, Costanzo MC, Fitzpatrick DA, de Groot PWJ,
Harris D, Hoyer LL, Hube B, Klis FM, Kodira C, Lennard
N, Logue ME, Martin R, Neiman AM, Nikolaou E, Quail
MA, Quinn J, Santos MC, Schmitzberger FF, Sherlock G,
Shah P, Silverstein KAT, Skrzypek MS, Soll D, Staggs R,
Stansfield I, Stumpf MPH, Sudbery PE, Srikantha T, Zeng
Q, Berman J, Berriman M, Heitman J, Gow NAR, Lorenz
MC, Birren BW, Kellis M, Cuomo CA (2009) Evolution of
pathogenicity and sexual reproduction in eight Candida genomes.
Nature 459(7247):657–662. doi:10.1038/nature08064
43. Bennett RJ (2009) A Candida-based view of fungal sex and
pathogenesis. Genome Biol 10(7):230. doi:10.1186/gb-2009-
10-7-230
44. Zhang J, Hollis RJ, Pfaller MA (1997) Variations in DNA
subtype and antifungal susceptibility among clinical isolates of
Candida tropicalis. Diagn Microbiol Infect Dis 27(3):63–67
45. Fricke S, Fricke C, Schimmelpfennig C, Oelkrug C, Schönfelder
U, Blatz R, Zilch C, Faber S, Hilger N, Ruhnke M, Rodloff AC
(2010) A real-time PCR assay for the differentiation of Candida
species. J Appl Microbiol 109(4):1150–1158. doi:10.1111/
j.1365-2672.2010.04736.x
46. Williams DW, Wilson MJ, Lewis MA, Potts AJ (1995)
Identification of Candida species by PCR and restriction
fragment length polymorphism analysis of intergenic spacer
regions of ribosomal DNA. J Clin Microbiol 33(9):2476–2479
47. Kanbe T, Horii T, Arishima T, Ozeki M, Kikuchi A (2002) PCR-
based identification of pathogenic Candida species using primer
mixes specific to Candida DNA topoisomerase II genes. Yeast
19(11):973–989. doi:10.1002/yea.892
48. Schabereiter-Gurtner C, Selitsch B, Rotter ML, Hirschl AM,
Willinger B (2007) Development of novel real-time PCR assays
for detection and differentiation of eleven medically important
Aspergillus and Candida species in clinical specimens. J Clin
Microbiol 45(3):906–914. doi:10.1128/JCM.01344-06
49. Quiles-Melero I, Garcia-Rodriguez J, Romero-Gomez MP,
Gomez-Sanchez P, Mingorance J (2010) Rapid identification of
yeasts from positive blood culture bottles by pyrosequencing.
Eur J Clin Microbiol Infect Dis. doi:10.1007/s10096-010-1045-5
50. Liguori G, Lucariello A, Colella G, De Luca A, Marinelli P
(2007) Rapid identification of Candida species in oral rinse
solutions by PCR. J Clin Pathol 60(9):1035–1039. doi:10.1136/
jcp.2006.040782
51. Bustamante CI (2005) Treatment of Candida infection: a view
from the trenches! Curr Opin Infect Dis 18(6):490–495
52. Bougnoux ME, Kac G, Aegerter P, Fagon JY, d’Enfert C (2008)
Candidemia and candiduria in critically ill patients admitted to
intensive care units in France: incidence, molecular diversity,
management and outcome. Intensive Care Med 34(2):292–299.
doi:10.1007/s00134-007-0865-y
53. Carey AJ, Saiman L, Polin RA (2008) Hospital-acquired infections
in the NICU: epidemiology for the new millennium. Clin Perinatol
35(1):223–249. doi:10.j.clp.2007.1/j.clp.2007.11.014
54. Shorr AF, Tabak YP, Johannes RS, Sun X, Spalding J, Kollef MH
(2009) Candidemia on presentation to the hospital: development and
validation of a risk score. Crit Care 13(5):R156. doi:10.1186/cc8110
55. Cisterna R, Ezpeleta G, Telleria O, Guinea J, Regueiro B,
Garcia-Rodriguez J, Esperalba J (2010) Nationwide sentinel
surveillance of bloodstream Candida infections in 40 tertiary
care hospitals in Spain. J Clin Microbiol 48(11):4200–4206.
doi:10.1128/JCM.00920-10
56. Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A,
Colombo AL (2010) Epidemiology of opportunistic fungal
infections in Latin America. Clin Infect Dis 51(5):561–570.
doi:10.1086/655683
57. Kojic EM, Darouiche RO (2004) Candida infections of medical
devices. Clin Microbiol Rev 17(2):255–267. doi:10.1128/
cmr.17.2.255-267.2004
58. Achkar JM, Fries BC (2010) Candida infections of the
genitourinary tract. Clin Microbiol Rev 23(2):253–273.
doi:10.1128/CMR.00076-09
59. Jain N, Kohli R, Cook E, Gialanella P, Chang T, Fries BC (2007)
Biofilm formation by and antifungal susceptibility of Candida
isolates from urine. Appl Environ Microbiol 73(6):1697–1703.
doi:10.1128/aem.02439-06
60. Pfaller MA (1992) Laboratory aids in the diagnosis of invasive
candidiasis. Mycopathologia 120(2):65–72
61. Viale P (2009) Candida colonization and candiduria in critically
ill patients in the intensive care unit. Drugs 69:51–57.
doi:10.2165/11315640-000000000-00000
62. Paul N, Mathai E, Abraham OC, Michael JS, Mathai D (2007)
Factors associated with candiduria and related mortality. J Infect
55(5):450–455. doi:10.j.clp.2007.1/j.jinf.2007.06.010
63. Binelli CA, Moretti ML, Assis RS, Sauaia N, Menezes PR,
Ribeiro E, Geiger DC, Mikami Y, Miyaji M, Oliveira MS,
Barone AA, Levin AS (2006) Investigation of the possible
association between nosocomial candiduria and candidaemia.
Clin Microbiol Infect 12(6):538–543. doi:10.1111/j.1469-
0691.2006.01435.x
64. Munoz P, Giannella M, Fanciulli C, Guinea J, Valerio M, Rojas
L, Rodriguez-Creixems M, Bouza E (2010) Candida tropicalis
fungaemia: incidence, risk factors and mortality in a general
hospital. Clin Microbiol Infect. doi:10.1111/j.1469-
0691.2010.03338.x
65. Kothavade RJ, Kura MM, Valand AG, Panthaki MH (2010)
Candida tropicalis: its prevalence, pathogenicity and increasing
resistance to fluconazole. J Med Microbiol 59(Pt 8):873–880.
doi:10.1099/jmm.0.013227-0
66. Colombo AL, Guimarães T, Silva LRBF, Monfardini LPA,
Cunha AKB, Rady P, Alves T, Rosas RC (2007) Prospective
observational study of candidemia in São Paulo, Brazil:
Incidence rate, epidemiology, and predictors of mortality. Infect
Control Hosp Epidemiol 28(5):570–576. doi:10.1086/513615
67. Falagas ME, Roussos N, Vardakas KZ (2010) Relative frequency
of albicans and the various non-albicans Candida spp among
candidemia isolates from inpatients in various parts of the world:
a systematic review. Int J Infect Dis 14(11):954–966. doi:10.j.
clp.2007.1/j.ijid.2010.04.006
68. Paulo C, Mourão C, Veiga PM, Marques JM, Rocha G, Alves
AF, Querol A, Meliço-Silvestre AA, Gonçalves I, Flores O,
Clemente C, Gonçalves T (2009) Retrospective analysis of
clinical yeast isolates in a hospital in the centre of Portugal:
spectrum and revision of the identification procedures. Med
Mycol 19(1):1–10. doi:10.1080/13693780802709081
69. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive
Candidiasis: a persistent public health problem. Clin Microbiol
Rev 20(1):133–163. doi:10.1128/cmr.00029-06
70. Chen K, Chen Y, Lin Y, Chou H, Li S (2009) The molecular
epidemiology of serial Candida tropicalis isolates from ICU
patients as revealed by multilocus sequence typing and pulsed-
field gel electrophoresis. Infect Genet Evol 9(5):912–920.
doi:10.j.clp.2007.1/j.meegid.2009.06.011
71. Pappas Peter G, Kauffman Carol A, Andes D, Benjamin J,
Daniel K, Calandra Thierry F, Edwards John E, Filler Scott G,
Fisher John F, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC,
Rex John H, Walsh Thomas J, Sobel Jack D (2009) Clinical
practice guidelines for the management of Candidiasis: 2009
1410 Eur J Clin Microbiol Infect Dis (2012) 31:1399–1412
update by the infectious diseases society of America. Clin Infect
Dis 48(5):503–535. doi:10.1086/596757
72. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA,
Tendolkar S, Diekema DJ (2009) Comparison of results of
fluconazole and voriconazole disk diffusion testing for Candida
spp. with results from a central reference laboratory in the
ARTEMIS DISK Global Antifungal Surveillance Program.
Diagn Microbiol Infect Dis 65(1):27–34. doi:10.j.clp.2007.1/j.
diagmicrobio.2009.05.007
73. Negri M, Henriques M, Svidzinski TIE, Paula CR, Oliveira R
(2009) Correlation between Etest®, disk diffusion, and micro-
dilution methods for antifungal susceptibility testing of Candida
species from infection and colonization. J Clin Lab Anal 23
(5):324–330. doi:10.1002/jcla.20337
74. Desnos-Ollivier M, Bretagne S, Bernede C, Robert V, Raoux D,
Chachaty E, Forget E, Lacroix C, Dromer F (2008) Clonal
population of flucytosine-resistant Candida tropicalis from blood
cultures, Paris, France. Emerg Infect Dis 14(4):557–565
75. Bedini A, Venturelli C, Mussini C, Guaraldi G, Codeluppi M,
Borghi V, Rumpianesi F, Barchiesi F, Esposito R (2006)
Epidemiology of candidaemia and antifungal susceptibility
patterns in an Italian tertiary-care hospital. Clin Microbiol Infect
12(1):75–80. doi:10.1111/j.1469-0691.2005.01310.x
76. Krcmery V (1999) Torulopsis glabrata an emerging yeast
pathogen in cancer patients. Int J Antimicrob Agents 11(1):1–6
77. Kumar C, Kumar S, Menon T (2006) Phospholipase and
proteinase activities of clinical isolates of Candida from
immunocompromised patients. Mycopathologia 161(4):213–
218. doi:10.1007/s11046-005-0157-4
78. Hoyer LL, Fundyga R, Hecht JE, Kapteyn JC, Klis FM, Arnold J
(2001) Characterization of agglutinin-like sequence genes from
non-albicans Candida and phylogenetic analysis of the ALS
family. Genetics 157(4):1555–1567
79. Yang Y (2003) Virulence factors of Candida species. J Microbiol
Immunol Infect 36(4):223–228
80. Silva S, Negri M, Henriques M, Oliveira R, Williams D,
Azeredo J (2010) Silicone colonization by non-Candida albicans
Candida species in the presence of urine. J Med Microbiol 59(Pt
7):747–754. doi:10.1099/jmm.0.017517-0
81. Silva S, Hooper SJ, Henriques M, Oliveira R, Azeredo J, Williams
DW (2011) The role of secreted aspartyl proteinases in Candida
tropicalis invasion and damage of oral mucosa. Clin Microbiol
Infect 17(2):264–272. doi:10.1111/j.1469-0691.2010.03248.x
82. Silva S, Negri M, Henriques M, Oliveira R, Williams DW,
Azeredo J (2011) Adherence and biofilm formation of non-
Candida albicans Candida species. Trends Microbiol 19(5):241–
247. doi:10.j.clp.2007.1/j.tim.2011.02.003
83. Biasoli MS, Tosello ME, Luque AG, Magaró HM (2010)
Adherence, colonization and dissemination of Candida dublin-
iensis and other Candida species. Med Mycol 48(2):291–297.
doi:10.1080/13693780903114942
84. Negri M, Silva S, Henriques M, Azeredo J, Svidzinski T,
Oliveira R (2011) Candida tropicalis biofilms: artificial urine,
urinary catheters and flow model. Med Mycol 49(7):739–747
85. Hasan F, Xess I, Wang X, Jain N, Fries BC (2009) Biofilm
formation in clinical Candida isolates and its association with
virulence. Microbes Infect 11(8–9):753–761. doi:10.j.clp.2007.1/
j.micinf.2009.04.018
86. Blankenship JR, Mitchell AP (2006) How to build a biofilm: a
fungal perspective. Curr Opin Microbiol 9(6):588–594. doi:10.j.
clp.2007.1/j.mib.2006.10.003
87. Kumamoto CA (2002) Candida biofilms. Curr Opin Microbiol 5
(6):608–611. doi:10.j.clp.2007.1/S1369-5274(02)00371-5
88. Douglas LJ (2003) Candida biofilms and their role in infection.
Trends Microbiol 11(1):30–36. doi:10.j.clp.2007.1/S0966-842X
(02)00002-1
89. Al-Fattani MA, Douglas LJ (2006) Biofilm matrix of Candida
albicans and Candida tropicalis: chemical composition and role
in drug resistance. J Med Microbiol 55(8):999–1008.
doi:10.1099/jmm.0.46569-0
90. Silva S, Henriques M, Martins A, Oliveira R, Williams D,
Azeredo J (2009) Biofilms of non-Candida albicans Candida
species: quantification, structure and matrix composition. Med
Mycol 47(7):681–689. doi:10.1080/13693780802549594
91. Al-Dhaheri RS, Douglas LJ (2008) Absence of amphotericin B-
tolerant persister cells in biofilms of some Candida species.
Antimicrob Agents Chemother 52(5):1884–1887. doi:10.1128/
aac.01473-07
92. Loeffler J, Hagmeyer L, Hebart H, Henke N, Schumacher U,
Einsele H (2000) Rapid detection of point mutations by
fluorescence resonance energy transfer and probe melting curves
in Candida species. Clin Chem 46(5):631–635
93. Gotz F (2002) Staphylococcus and biofilms. Mol Microbiol 43
(6):1367–1378
94. Bendel CM (2003) Colonization and epithelial adhesion in the
pathogenesis of neonatal candidiasis. Semin Perinatol 27(5):357–
364. doi:10.j.clp.2007.1/S0146-0005(03)00059-4
95. Bendel C, Hostetter M (1993) Distinct mechanisms of epithelial
adhesion for Candida albicans and Candida tropicalis. Identifi-
cation of the participating ligands and development of inhibitory
peptides. J Clin Invest 92:1840–1849. doi:10.1172/JCI116775
96. Klotz SA, Drutz DJ, Harrison JL, Huppert M (1983) Adherence
and penetration of vascular endothelium by Candida yeasts.
Infect Immun 42(1):374–384
97. Sohn K, Senyürek I, Fertey J, Königsdorfer A, Joffroy C, Hauser
N, Zelt G, Brunner H, Rupp S (2006) An in vitro assay to study
the transcriptional response during adherence of Candida
albicans to different human epithelia. FEMS Yeast Res 6
(7):1085–1093. doi:10.1111/j.1567-1364.2006.00130.x
98. Miyauchi M, Giummelly P, Yazawa S, Okawa Y (2007) Adhesion
of Candida albicans to HeLa cells: studies using polystyrene
beads. Biol Pharm Bull 30(3):588–590. doi:10.1248/bpb.30.588
99. Jayatilake J, Samaranayake Y, Cheung L, Samaranayake L (2006)
Quantitative evaluation of tissue invasion by wild type, hyphal and
SAP mutants of Candida albicans, and non-albicans Candida
species in reconstituted human oral epithelium. J Oral Pathol Med
35(8):484–491. doi:10.1111/j.1600-0714.2006.00435.x
100. Arendrup M, Horn T, Frimodt-Moller N (2002) In vivo
pathogenicity of eight medically relevant Candida species in an
animal model. Infection 30(5):286–291. doi:10.1007/s15010-
002-2131-0
101. Ghannoum MA (2000) Potential role of phospholipases in
virulence and fungal pathogenesis. Clin Microbiol Rev 13
(1):122–143. doi:10.1128/cmr.13.1.122-143.2000
102. Naglik JR, Challacombe SJ, Hube B (2003) Candida albicans
secreted aspartyl proteinases in virulence and pathogenesis.
Microbiol Mol Biol Rev 67(3):400–428. doi:10.1128/
mmbr.67.3.400-428.2003
103. Prakobphol A, Leffler H, Fisher SJ (1994) Specific adherence of
Candida tropicalis to lysophospholipids. Biochemistry 33
(32):9496–9503
104. Kantarciôlu AS, Yücel A (2002) Phospholipase and protease
activities in clinical Candida isolates with reference to the
sources of strains. Mycoses 45(5–6):160–165. doi:10.1046/
j.1439-0507.2002.00727.x
105. Fu Y, Ibrahim AS, Fonzi W, Zhou X, Ramos CF, Ghannoum MA
(1997) Cloning and characterization of a gene (LIP1) which
encodes a lipase from the pathogenic yeast Candida albicans.
Microbiology 143(Pt 2):331–340
106. Price M, Wilkinson I, Gentry L (1982) Plate method for detection
of phospholipase activity in Candida albicans. Sabouraudia 20:7–
14
Eur J Clin Microbiol Infect Dis (2012) 31:1399–1412 1411
107. da Costa K, Ferreira J, Komesu M, Candido R (2009) Candida
albicans and Candida tropicalis in oral candidosis: quantitative
analysis, exoenzyme activity, and antifungal drug sensitivity.
Mycopathologia 167(2):73–79. doi:10.1007/s11046-008-9154-8
108. Furlaneto-Maia L, Specian A, Bizerra F, de Oliveira M,
Furlaneto M (2007) In vitro evaluation of putative virulence
attributes of oral isolates of Candida spp. obtained from elderly
healthy individuals. Mycopathologia 166(4):209–217. doi:10.1007/
s11046-008-9139-7
109. Cafarchia C, Romito D, Coccioli C, Camarda A, Otranto D
(2008) Phospholipase activity of yeasts from wild birds and
possible implications for human disease. Med Mycol 46(5):429–
434. doi:10.1080/13693780701885636
110. Luo G, Samaranayake LP, Yau JYY (2001) Candida species
exhibit differential in vitro hemolytic activities. J Clin Microbiol
39(8):2971–2974. doi:10.1128/jcm.39.8.2971-2974.2001
111. Watanabe T, Takano M, Murakami M, Tanaka H, Matsuhisa A,
Nakao N, Mikami T, Suzuki M, Matsumoto T (1999) Character-
ization of a haemolytic factor fromCandida albicans. Microbiology
145(3):689–694. doi:10.1099/13500872-145-3-689
112. Manns JM,MosserDM,BuckleyHR (1994) Production of a hemolytic
factor by Candida albicans. Infect Immun 62(11):5154–5156
113. Kumar VG, Latha R, Vedhagiri K, Sathiamoorthi T, Jayarani G,
Sasikala R, Selvin J, Natarajaseenivasan K (2009) Phospholipase
C, proteinase and hemolytic activities of Candida spp. isolated
from pulmonary tuberculosis patients. J Mycol Med 19(1):3–10.
doi:10.j.clp.2007.1/j.mycmed.2008.11.002
114. Chang HC, Leaw SN, Huang AH, Wu TL, Chang TC (2001)
Rapid identification of yeasts in positive blood cultures by a
multiplex PCR method. J Clin Microbiol 39(10):3466–3471.
doi:10.1128/JCM.39.10.3466-3471.2001
115. Mokaddas EM, Al-Sweih NA, Khan ZU (2007) Species
distribution and antifungal susceptibility of Candida blood-
stream isolates in Kuwait: a 10-year study. J Med Microbiol 56
(2):255–259. doi:10.1099/jmm.0.46817-0
116. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L,
Grillot R (2006) Candidaemia in Europe: epidemiology and
resistance. Int J Antimicrob Agents 27(5):359–366. doi:10.j.
clp.2007.1/j.ijantimicag.2006.01.002
117. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN
(2010) Variation in Candida spp. distribution and antifungal
resistance rates among bloodstream infection isolates by patient
age: report from the SENTRY Antimicrobial Surveillance
Program (2008–2009). Diagn Microbiol Infect Dis 68(3):278–
283. doi:10.j.clp.2007.1/j.diagmicrobio.2010.06.015
118. Dorko E, Pilipčinec E, Tkáčiková L (2002) Candidal urinary
tract infections caused by non-albicans Candida species. Folia
Microbiol 47(2):182–184. doi:10.1007/BF02817679
1412 Eur J Clin Microbiol Infect Dis (2012) 31:1399–1412
